Fragmentation, Often a Killer: The #1 FOAK Song
At the beginning, it’s simple. Not easy—never easy—but simple. There is one problem, and it’s enormous: can this technology work? For years, that’s the mountain. Teams gather around it, capital circles it, skeptics point at it, believers climb it. Everything reduces to a single question: is this even possible? And then, one day, it is. The chemistry works, the pathway closes, the test results come back clean. Somewhere in a lab or a pilot unit, a door swings open. The big problem is gone. And that’s when the real trouble begins.
Because the moment you solve the one problem, it doesn’t disappear. It breaks. One problem becomes ten—permitting, financing, offtake, construction, commissioning, insurance, policy, feedstock logistics, currency risk, community acceptance. Each one smaller than the original mountain, each one, in isolation, manageable. But not one at a time. All at once.
We call these projects FOAK—First-of-a-Kind. But that’s not what kills them. They don’t die because they are first. They die because they fragment. FOAK, it turns out, stands for something else: Fragmentation, Often a Killer.
Consider where we are right now in sustainable aviation fuel.
Universal Fuel Technologies has demonstrated something quietly profound. Using independent testing at Washington State University, its Flexiforming process converts a low-value HEFA byproduct—naphtha, often up to 20% of output—into the aromatic molecules that jet fuel requires.
In testing, a blend of roughly 16% Flexiforming-derived aromatics and 84% HEFA paraffinic fuel met key ASTM screening properties: density, viscosity, flash point, even a freeze point of -43.5°C. That matters because conventional jet fuel contains 8–25% aromatics, and today’s SAF pathways—HEFA, Fischer–Tropsch, ethanol-to-jet—don’t produce them. The result has been a structural dependency: renewable fuels must still be blended with fossil jet to function.
Flexiforming closes that loop. Not with a billion-dollar rebuild, but with a bolt-on step, using the system’s own byproducts. It is, on its face, an elegant solution—efficient, integrated, capital-light. A door opens.
But this is no longer a technology story. It’s a system story. Because behind that door are others: ASTM D4054 qualification, catalyst durability over time, integration into existing HEFA facilities, commercial partnerships, project finance. The chemistry is solved. The system problem has just begun.
Step forward one stage, into a different sector of the bioeconomy. Unibio is not proving anything in a lab; it is preparing to build—an initial 50,000-ton single-cell protein facility, with ambitions to scale beyond 300,000 tons. This is the physical scale-up phase: steel, concrete, timelines, capital deployment. The problem is no longer “does it work?” but can it be built on time, on budget, at spec, with reliable operations, into a market that absorbs it? Another door opens.
Step forward again. A driver pulls up to the pump, fills with E15, and saves sixty cents a gallon. This is the market completion phase. No maze at the pump, no ASTM debate, no financing structure—just a price, a product, and a decision.
These are not separate stories. They are the same system, seen at three stages: UFT as system integration, Unibio as physical scale-up, E15 as market absorption. And between each stage, the number of problems doesn’t shrink. It multiplies.
In the early phase, progress feels like a road—a Yellow Brick Road. Follow it far enough, and you arrive. But that’s not what happens. The road becomes a corridor, the corridor becomes a maze, each door you open leads to more doors, the horizon moves farther away the faster you walk toward it. And then something stranger happens. The problem, once massive and singular, becomes small enough to grasp—and breaks into pieces. Too many pieces.
This is where projects don’t fail. They exhaust. Like the hunters of old, the system doesn’t bring down the prey with a single blow. It runs alongside it, hour after hour, until the great animal—strong, capable, fully alive—simply can’t keep going. Not defeated. Worn down.
This is the hidden dynamic of the bioeconomy today—not a lack of innovation, not a lack of capital, not even a lack of demand, but a mismatch between the number of problems that must be solved and the number of problems that can be solved at once.
And here is the paradox. Flexiforming may be simple, efficient, even cheap as technologies go. But simplicity at the unit level does not eliminate complexity at the system level. In fact, it often accelerates it, because each solved constraint reveals the next layer of dependency.
So how do projects survive the maze? Not by solving everything, but by reducing fragmentation faster than it accumulates. That means designing bolt-on solutions, not standalone empires; using existing infrastructure, not rebuilding the world; partnering across the chain, not carrying every burden alone; solving structural constraints, not just adding capacity; and aligning capital and policy with technical progress, so projects are financed and approved as they de-risk—not after.
In other words: not just innovation—coordination.
Because the prize at the end of the maze is enormous. For aviation, it is nothing less than 100% drop-in synthetic fuel, produced without fossil blending, using existing assets, at improving yields and economics—a system that no longer depends on what it is trying to replace.
What begins as a road becomes a labyrinth. Each door opens more doors. The horizon moves farther away. The problem breaks into pieces. And in the end, like the hunters of old, the system is not defeated—it is exhausted.
Unless it learns to move through the maze together.
Category: Top Stories
